Part 4: Indolent B-Cell Non-Hodgkin Lymphoma

Robert Frank Cornell, MD

Hematology/Oncology Fellow, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

Timothy S. Fenske, MD

Associate Professor of Medicine, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

Question 4

After initial therapy, the patient achieves a complete remission. Which of the following is NOT considered an appropriate option at this point?

  •  Ibritumomab tiuxetan (consolidation with radioimmunotherapy)
  •  Extended or “maintenance” therapy with single-agent rituximab
  •  Observation alone
  •  Autologous hematopoietic stem cell transplant

Updated 02/15/2012 • jdw | Copyright ©2014 Turner White Communications